Advertisement
Home »

Differences in asthma-related outcomes by anti-IL-5 biologics, omalizumab, and dupilumab based on blood eosinophil counts.

Jan 08, 2024

ABOUT THE EXPERTS

  • Yuya Kimura

    Clinical Research Center, National Hospital Organization Tokyo Hospital, Tokyo, Japan.

    Maho Suzukawa

    Clinical Research Center, National Hospital Organization Tokyo Hospital, Tokyo, Japan.

    Norihiko Inoue

    Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.

    Department of Clinical Data Management and Research, Clinical Research Center, National Hospital Organization Headquarters, Tokyo, Japan.

    Shinobu Imai

    Division of Pharmacoepidemiology, Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, Tokyo, Japan.

    Hiromasa Horiguchi

    Department of Clinical Data Management and Research, Clinical Research Center, National Hospital Organization Headquarters, Tokyo, Japan.

    Manabu Akazawa

    Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.

    Hirotoshi Matsui

    Department of Respiratory Medicine, National Hospital Organization Tokyo Hospital, Tokyo, Japan.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement